Funding extends internationally acclaimed Alzheimer’s research

Discovering new methods and medications to stop or minimize the effects of late-onset Alzheimer's disease is the goal of the Indiana University School of Medicine’s new $48.8 million National Institutes of Health funding. Alzheimer's research represents the second largest NIH-funded research program at the IU School of Medicine and will greatly advance our researchers' quest to create new treatments for this debilitating disease, which affects 55 million people around the world. 

The second largest federally funded grant in the school's history, this funding renewal from the National Institute on Aging — the largest branch for Alzheimer's disease research within the NIH — will support research for the next five years. It is the latest recognition of IU as a leading consortium studying late-onset Alzheimer's disease, when symptoms occur in people in their mid-60s or older. And, this award furthers IU's leadership position internationally in Alzheimer's research. The largest federally funded grant ever awarded to the university is $52 million over a five-year period for the study of early-onset Alzheimer's disease — research led by neurologist and neuroscientist Dr. Liana Apostolova.

For securing this newest $48.8 million grant renewal from the NIH, I am deeply grateful to Bruce Lamb, PhD, executive director of the IU School of Medicine's Stark Neurosciences Research Institute, and to all the researchers who play a critical role in this vital work: Professor Paul Territo, PhD, Assistant Professor Adrian Oblak, PhD, and everyone on their teams.

Pamela Whitten

President
Indiana University